CA
NZ
UK
AU
IND
US
Smurfit Westrock plc (NYSE: SW) awarded Garren Ben 56 shares at $0 per share, bringing his reported holdings to 14,996 shares. The transaction was recorded on September 10, 2026, under transaction code A.
Veracyte, Inc. (NASDAQ: VCYT) completed its acquisition of Convergent Genomics Inc. for $150 million in aggregate cash consideration, subject to customary purchase price adjustments. The transaction took effect on September 14, 2026, with Convergent continuing as aWholly Owned Subsidiaryof Veracyte.
Smurfit Westrock plc (NYSE: SW) awarded Sellier Laurent 140 shares at $0 per share on September 10, 2026. The filing also reported a separate award of derivative securities.
Smurfit Westrock plc (NYSE: SW) awarded director FergusonMchugh MaryLynn 48 shares at $0 per share. The transaction represented about 0.6% of her resulting holding.
Smurfit Westrock plc (NYSE: SW) awarded director Alan D. Wilson 674 shares at $0 per share on September 10, 2026. His disclosed ownership after the award stood at 67,580 shares, making the grant about 1.0% of the resulting holding.
Yarrow Bioscience, Inc. (NASDAQ: YARW) is raising approximately $161.8 million in expected net proceeds through a common-stock offering priced at $26.00 per share. The transaction covers 5,769,231 shares, while underwriters exercised a 30-day option in full for up to 865,384 additional shares.
Lewis Brings PublicManufacturingExperience
Smurfit Westrock plc (NYSE: SW) awarded director Finan Irial 75 shares at $0 per share. The transaction date was September 10, 2026.
HUNTINGTON INGALLS INDUSTRIES, INC. (NYSE: HII) awarded derivative securities to former Ingalls executive Brian D. Blanchette on September 11, 2026, with the transaction representing about 0.5% of his resulting derivative-securities holding. Blanchette held 2,984 derivative securities after the award.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) said its MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 in major depressive disorder failed to achieve its primary efficacy endpoint. The result concerns a monotherapy study in adult participants, while the treatment’s reported safety profile included no new safety signals.
Please wait processing your request...